Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn’s disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years

Byong Duk Ye; Ken Sugimoto; Jae Hee Cheon; Christopher Gasink; Yuya Imai; Bryan Wahking; Jianmin Zhuo; Shiho Kawamura; Toshifumi Hibi∥

doi:10.5217/ir.2025.00285

July 10, 2026Intestinal ResearchOpen Access

Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn’s disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to evaluate the efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn's disease over a long-term period.
Subpopulation analysis of Asian patients from the UNITI/IM-UNITI long-term extension study.
Assessment of treatment efficacy and adverse events over 5 years.
Ustekinumab demonstrated effective long-term control of Crohn's disease activity.
Adverse events were noted but overall safety profile was acceptable.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Shows efficacy and safety of ustekinumab in Asian patients with Crohn’s disease, suggesting a viable long-term treatment option.

Abstract

Crohn's disease (CD) is a progressive inflammatory bowel disease (IBD) that requires effective long-term therapy to control disease activity and to stop accumulating bowel damage.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/6a53315f4f7abc118aded838 https://doi.org/10.5217/ir.2025.00285

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn’s disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn’s disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading